FIRST CLINICAL RESEARCH SUPPORTED BY RAKFOND/RUSSCO GRANT STARTS AT N. N. BLOKHIN NATIONAL MEDICAL RESEARCH CENTRE OF ONCOLOGY
Alexey Rumyantsev is the principal researcher and winner of the RUSSCO/RakFond award
The preparation was finished and first patients have been recruited for the clinical study of one of the winners of the first joint award of the Russian Society of Clinical Oncology (RUSSCO) and the Foundation for Cancer Research Support (RakFond). The aim of the study is to evaluate the efficacy and safety of a new regimen for the prevention of nausea and vomiting in chemotherapy. Up to 130 patients receiving chemotherapy with a high incidence of nausea and vomiting as side effects will be recruited for this open, randomized Phase II study. The new regimen of drug therapy will be compared with an active treatment – the current gold standard in clinical practice. The primary endpoint of the study will be control over nausea, secondary endpoint – the frequency of responses and the level of sedation (sedative effect is one of the undesirable effects of antiemetics). The study will continue until May 2019, with the recruitment of patient planned to stop in March 2019. If successful, the results of the study will for basis for further study and introduction of a new accessible mode of accompanying therapy to improve the quality of life of cancer patients.
For more information about the study, see ClinicalTrials.gov: Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis (OlaCINV)
With all questions related to the study, please contact the principal investigator, Alexey Rumyantsev: email@example.com.